The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Open accessAbstract
BACKGROUND: Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex. METHODS: Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study. The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months. We gave everolimus orally, at a dose of 3.0 mg per square meter of body-surface area, to achieve a trough concentration of 5 to 15 ng per milliliter. RESULTS: We enrolled 28 patients. Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%). Marked reductions were seen within 3 months and were sustained. There were no new lesions, worsening hydrocephalus, evidence of increased intracranial pressure, or necessity for surgical resection or other therapy for subependymal giant-cell astrocytoma. Of the 16 patients for whom 24-hour video electroencephalography data were available, seizure frequency for the 6-month study period (vs. the previous 6-month period) decreased in 9, did not change in 6, and increased in 1 (median change, -1 seizure; P=0.02). The mean (±SD) score on the validated Quality-of-Life in Childhood Epilepsy questionnaire (on which scores can range from 0 to 100, with higher scores indicating a better quality of life) was improved at 3 months (63.4±12.4) and 6 months (62.1±14.2) over the baseline score (57.8±14.0). Single cases of grade 3 treatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia were reported. CONCLUSIONS: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Self-citationThe TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria
Roach, E. S., Gomez, M. R., & Northrup, H. (1998) · Journal of Child Neurology · doi:10.1177/088307389801301206 · Cited by 1,081
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Self-citationEaston, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Subependymal giant cell tumors in tuberous sclerosis complex
Goh, S., Butler, W., & Thiele, E. A. (2004) · Neurology · doi:10.1212/01.wnl.0000142039.14522.1a · Cited by 262
Chan, J. A., Zhang, H., Roberts, P. S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K., & Kwiatkowski, D. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1236 · Cited by 258
The Growing Role of mTOR in Neuronal Development and Plasticity
Jaworski, J., & Sheng, M. (2006) · Molecular Neurobiology · doi:10.1385/mn:34:3:205 · Cited by 239
Cited by
Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Self-citationEpidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Challenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Recent progress in pancreatic cancer
Wolfgang, C. L., Herman, J. M., Laheru, D. A., Klein, A. P., Erdek, M. A., Fishman, E. K., & Hruban, R. H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21190 · Cited by 910
Krueger, D. A., Northrup, H., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.002 · Cited by 854
Self-citationHenske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Self-citationPTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Self-citationLipton, J. O., & Sahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 736
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Schultze, S. M., Hemmings, B. A., Niessen, M., & Tschopp, O. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002109 · Cited by 540
Lim, J. S., Kim, W.-I., Kang, H.-C., Kim, S. H., Park, A. H., Park, E. K., Cho, Y.-W., Kim, S., Kim, H. M., Kim, J. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3824 · Cited by 518
Parsons, D. W., Roy, A., Yang, Y., Wang, T., Scollon, S., Bergstrom, K., Kerstein, R. A., Gutierrez, S., Petersen, A. K., Bavle, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5699 · Cited by 491
Wang, Y., Springer, S., Zhang, M., McMahon, K. W., Kinde, I., Dobbyn, L., Ptak, J., Brem, H., Chaichana, K., Gallia, G. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511694112 · Cited by 454
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427
mTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Krueger, D. A., Wilfong, A. A., Holland‐Bouley, K., Anderson, A. E., Agricola, K., Tudor, C., Mays, M., Lopez, C. M., Kim, M., & Franz, D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23960 · Cited by 389
Self-citationThe mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368
Cao, K., Graziotto, J. J., Blair, C. D., Mazzulli, J. R., Erdos, M. R., Krainc, D., & Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002346 · Cited by 350
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Multi-compartment microscopic diffusion imaging
Kaden, E., Kelm, N. D., Carson, R. P., Does, M. D., & Alexander, D. C. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.06.002 · Cited by 345
Davies, D. M., de Vries, P. J., Johnson, S. R., McCartney, D. L., Cox, J. A., Serra, A. L., Watson, P. C., Howe, C. J., Doyle, T., Pointon, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0445 · Cited by 309
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5740 · Cited by 309
Manford, M. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8394-2 · Cited by 299
Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments
Ruda, R., Bello, L., Duffau, H., & Soffietti, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos199 · Cited by 280
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., Byers, L. A., Xu, Y., Hess, K. R., Diao, L., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2940 · Cited by 280
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Verheijen, R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.787 · Cited by 278
Current treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
mTOR: A pathogenic signaling pathway in developmental brain malformations
Crino, P. B. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.07.008 · Cited by 266
Nanotechnology for angiogenesis: opportunities and challenges
Kargozar, S., Baino, F., Hamzehlou, S., Hamblin, M. R., & Mozafari, M. (2020) · Chemical Society Reviews · doi:10.1039/c8cs01021h · Cited by 262
Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations
Curatolo, P., Jóźwiak, S., & Nabbout, R. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.05.004 · Cited by 256
Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0345 · Cited by 253
Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Pestell, R. G., Tanowitz, H. B., Sotgia, F., & Lisanti, M. P. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.01.023 · Cited by 248
The genomic landscape of tuberous sclerosis complex
Martin, K. R., Zhou, W., Bowman, M. J., Shih, J., Au, K. S., Dittenhafer-Reed, K. E., Sisson, K. A., Koeman, J., Weisenberger, D. J., Cottingham, S. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15816 · Cited by 238
Self-citationAn epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Tye, C., Runicles, A. K., Whitehouse, A. J. O., & Alvares, G. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00751 · Cited by 177
Amplification of human interneuron progenitors promotes brain tumors and neurological defects
Eichmüller, O. L., Corsini, N. S., Vértesy, Á., Morassut, I., Scholl, T., Gruber, V.-E., Peer, A. M., Chu, J., Novatchkova, M., Hainfellner, J. A., et al. (2022) · Science · doi:10.1126/science.abf5546 · Cited by 163
Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Belousova, E., Frost, M. D., Sauter, M., Brakemeier, S., de Vries, P. J., Berkowitz, N., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180939 · Cited by 157
Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
Krueger, D. A., Sadhwani, A., Byars, A. W., de Vries, P. J., Franz, D. N., Whittemore, V. H., Filip‐Dhima, R., Murray, D., Kapur, K., & Sahin, M. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.494 · Cited by 133
Self-citationLong-term treatment of epilepsy with everolimus in tuberous sclerosis
Krueger, D. A., Wilfong, A. A., Mays, M., Talley, C. M., Agricola, K., Tudor, C., Capal, J., Holland-Bouley, K., & Franz, D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000003400 · Cited by 124
Self-citationTSC1/TSC2 signaling in the CNS
Han, J. M., & Sahin, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.02.001 · Cited by 105
Pathogenetic mechanisms of focal cortical dysplasia
Marin‐Valencia, I., Guerrini, R., & Gleeson, J. G. (2014) · Epilepsia · doi:10.1111/epi.12650 · Cited by 100
mTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86
Tsai, P., & Sahin, M. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834451c4 · Cited by 84
Sarnat, H. B., & Flores-Sarnat, L. (2015) · Brain and Development · doi:10.1016/j.braindev.2014.08.010 · Cited by 73
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis
Franz, D. N., & Weiss, B. D. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0269-4 · Cited by 58
Self-citationEvangelisti, C., Cenni, V., & Lattanzi, G. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12928 · Cited by 53
Zimmer, T. S., Broekaart, D. W. M., Gruber, V.-E., van Vliet, E. A., Mühlebner, A., & Aronica, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01028 · Cited by 48
Metadata
- Authors
- Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-04
- Volume
- 363
- Issue
- 19
- Pages
- 1801-1811
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2035495486
- Cited by
- 1,006
- References
- 27
- FWCI
- 56.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.